Biotech, cancer, Hedgehog
Infinity Starts Trial of Hedgehog Pathway Blocker
Luke Timmerman 10/16/08
Infinity Pharmaceuticals, the Cambridge, MA-based developer of cancer drugs, said today it has started an early-stage clinical trial of 30 to 50 patients with advanced solid tumors, or those that have spread. The company (NASDAQ: INFI) will test IPI-926, an orally-given blocker of the hedgehog pathway, which researchers say can play a central role in tumor growth when it becomes overactivated.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
